Bortezomib Intravenous and Docetaxel Injection, Concentrate
Determining the interaction of Bortezomib Intravenous and Docetaxel Injection, Concentrate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using bortezomib together with DOCEtaxel may increase the risk of nerve damage, which is a potential side effect of both medications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know if you develop vision abnormalities or weakness, numbness, pain, burning, and/or tingling in your hands, feet, or limbs. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported. During clinical trials, 37% of the patients experienced treatment emergent neuropathy. Of these, more than 70% had previously been treated with neurotoxic agents and more than 80% of these patients had signs or symptoms of peripheral neuropathy at baseline. The incidence of grade 3 neuropathy (i.e., that which interferes with activities of daily life) was 5% in patients without baseline neuropathy.
MANAGEMENT: Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling. Symptoms may improve or return to baseline in some patients upon discontinuation of bortezomib, although the complete time course of this toxicity has not been fully characterized.
- Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6
- "Product Information. Velcade (bortezomib)." Millennium Pharmaceuticals Inc, Cambridge, MA.
- Cavaletti G, Jakubowiak AJ "Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies." Leuk Lymphoma 51 (2010): 1178-87
Generic Name: bortezomib
Brand name: Velcade
Synonyms: Bortezomib (Intravenous)
Generic Name: docetaxel
Brand name: Taxotere, Docefrez
Synonyms: Docetaxel, DOCEtaxel
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bortezomib Intravenous-Docetaxel Intravenous
- Bortezomib Intravenous-Docosavit
- Bortezomib Intravenous-DocQLace Syrup
- Bortezomib Intravenous-Doculax
- Bortezomib Intravenous-Docuprene Tablets
- Bortezomib Intravenous-Docusate
- Docetaxel Injection, Concentrate-Bosentan
- Docetaxel Injection, Concentrate-Bosentan Tablets
- Docetaxel Injection, Concentrate-Bosentan Tablets for Oral Suspension
- Docetaxel Injection, Concentrate-Bosulif
- Docetaxel Injection, Concentrate-Bosutinib
- Docetaxel Injection, Concentrate-Botox